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A B S T R A C T
The human brain is a target of the aging process like other cell systems of the human body. Speciﬁc regions of the
human brain exhibit diﬀerential vulnerabilities to the aging process. Yet the underlying mechanisms that sustain
the preservation or deterioration of neurons and cerebral functions are unknown. In this review, we focus at-
tention on the role of lipids and the importance of the cross-regionally diﬀerent vulnerabilities in human brain
aging. In particular, we ﬁrst consider a brief approach to the lipidomics of human brain, the relationship be-
tween lipids and lipoxidative damage, the role of lipids in human brain aging, and the speciﬁc targets of li-
poxidative damage in human brain and during aging. It is proposed that the restricted set of modiﬁed proteins
and the functional categories involved may be considered putative collaborative factors contributing to neuronal
aging, and that mitochondrial ATP synthase is a key lipoxidative target in human brain aging.
1. Lipidomics of human brain
The natural history of lipids is related to the origin of life and
evolution of multicellularity [1]. The result is that all living organisms
and cell types have lipid membranes. Neurons and glial cells are not an
exception. Indeed, lipids supported and allowed the brain's evolution
toward complexity [2,3].
Among tissues of the human body, nervous tissue is one of the
richest in lipid content, representing 10–12% of the fresh weight and
50% of the dry matter [4]. In addition to their quantitative relevance,
lipids of the nervous system show great structural and functional di-
versity, with most lipid categories represented in neural cells as ex-
pressions of the diﬀerent needs and functions ascribed to them which
are related to the generation of membranes, cell signaling, and energy
storage [5,6].
A wide spectrum of functions, from motor to cognitive, are per-
formed by human brain thanks to the organization and activity of a
diversity of neural cells in a multitude of neuroanatomically and
functionally diﬀerent regions. It has been proposed that this diversity
among neural cells, and particularly neurons, is phenotypically
achieved, at least in part, through the expression of particular lipid
proﬁles [6]. This region-dependent lipidomic ﬁngerprint can play a key
role in the diﬀering vulnerability to aging exhibited by speciﬁc regions
of the human brain [6–8].
1.1. Lipids in whole human brain
Whole adult human brain contains a large amount and diversity of
lipid classes and lipid molecular species. Thus, in addition to the pre-
sence of diverse phospholipid classes, whole brain also contains a large
portion of sphingolipid species, as well as a great pool of cholesterol
and cholesterol metabolites [4] (see Fig. 1). Speciﬁcally, glyceropho-
spholipids (Gpl) represent about 4.5–5.4% of wet weight (4.2% in the
gray matter and 7% in the white). Among Gpl, ethanolamine glycer-
ophospholipids (EtnGpl) are numerically the main phospholipid
(35.6%) and most of these are ethanolamine plasmalogen (PE(P-);
50–60%). The fatty acid proﬁle of this lipid class indicates a large
content of polyunsaturated fatty acids (PUFAs), preferentially at sn-2
position [9,10]. The predominant form of choline glycerophospholipids
(ChoGpl) is phosphatidylcholine (PtdCho or PC; 32.8%), with PC(16:0/
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18:1) being the major molecular species [9,11]. The choline plasma-
logen (PC(P-))and the alkyl (PC(O-)) analogue account for only about
2% of total ChoGpl. The concentration of serine glycerophospholipids
(SerGpl) is about 16.6% of total phospholipids. They occur as phos-
phatidylserine (PtdSer or PS; more than 90%) and serine plasmalogen
(PS(P-)). Regarding the fatty acid proﬁle, they contain mainly stearic
acid (18:0), oleic acid (18:1n-9), and docosahexaenoic acid (DHA,
22:6n-3) [9,10]. Gray matter PSs are particularly rich in DHA. Inositol
glycerophospholipids (InoGpl) account for about 2.6% of the total
phospholipids. Phosphatidylinositol (PtdIno or PI) and tripho-
sphoinositide (PIP3) are the major lipids with only trace amounts of
diphosphoinositide (PIP2), with the main fatty acid components 18:0
and arachidonic acid (AA, 20:4n-6) [4,11]. Glycerophosphates (Gpl),
and speciﬁcally phosphatidic acid (PA), occur in low concentrations in
brain (about 2% of total phospholipids). Finally, diphosphatidylglycerol
(cardiolipin), mainly located in brain mitochondria, represents around
0.2% of phospholipids. The main fatty acids included in this phospho-
lipid fraction are palmitic acid (16:0), palmitoleic acid (16:1), 18:0,
18:1n-9, and linoleic acid (18:2n-6), with minor representation, if
present, of linolenic acid (18:3n-3) and AA [4,12].
Sphingolipids are a group of complex lipids present in particularly
large concentrations in human brain. This group of lipids consists of
sphingomyelin, cerebrosides, sulfatides, and gangliosides.
Sphingomyelin (SM) accounts for about 14.8% of sphingolipid content.
SM fatty acids are made up mainly of 18:0, lignoceric (24:0), and
nervonic (24:1) acids [11]. Cerebrosides amount to 15.8% of the total
lipids, mostly as galactosylceramide, and the fatty acid components
characteristically contain hydroxyl fatty acids (cerebronic (24 h:0) and
hydroxynervonic (24 h:1)) which account for more than 50% of the
total fatty acids [11]. Sulfatides are the only sulfosphingolipid present
in brain, and they account for about 6.2% of total lipids of brain. The
fatty acid composition of sulfatides is similar to that of cerebrosides
[11]. Finally, gangliosides are particularly abundant in brain. Stearic
acid (18:0) is the main fatty acid and forms over 80% of the total
ganglioside fatty acid content [4].
1.2. Lipid distribution in human brain: a cross-regional comparative
approach
The complexity of the adult human brain is reﬂected by its 900
neuroanatomically precise subdivisions [13]. Analogously to the
ﬁnding that there are region-speciﬁc transcriptomic [13] and proteomic
[14] ﬁngerprints, it may be proposed that the lipidome of each brain
structure or region is also diﬀerent. In this line, some recent studies
have used a lipidomic approach to analyze the lipid proﬁle of human
brain gray matter at the mitochondrial and microsomal levels in three
Fig. 1. Main adult human brain lipids: (1) major fatty acids present in adult human brain amounting to about 80–90% of total fatty acid proﬁle [19]; (2) glycerolipids
(GL) are fatty acid esters of glycerol and in human brain mostly comprise mono- and diacylglycerols; (3) glycerophospholipids includes distinct lipid classes based on
the nature of the head group linked to the phosphate at the sn-3 position of the glycerol backbone: Phosphatidylcholine (PC), phosphatidylethanolamine (PE),
phosphatidylserine (PS), and phosphatidylinositols (PI) are the main phospholipids present in human brain [4]; (4) representative sphingolipids present in human
brain are shown; and (5) cholesterol is the main sterol lipid presents in human brain. Lipid molecular species structures are adapted from LipidMaps (https://www.
lipidmaps.org/).
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diﬀerent regions of the human cerebral cortex: entorhinal cortex (EC),
hippocampus (HP), and prefrontal cortex (PFC) [15–17]. The results
show that, independently of the subcellular fraction and brain region,
the three major phospholipid classes are, in this order: ChoGpl, EtnGpl,
and SerGpl. Overall, ChoGpls comprise around 43–55% of total phos-
pholipids (43% in HP; 50% EC; and 55% PFC), and the main molecular
species are PC(16:0/18:1), PC(16:0/16:0), and PC(18:0/18:1). EtnGpls
represent about 28–36% of total phospholipids (36% in HP; 32.1% EC;
and 30% PFC), with the major molecular species (in this order): PE
(18:0/22:6), PE(18:0/20:4), PE(18:0/22:4), and PE(16:0/22:6). Finally,
SerGpls represent around 15–21% of total phospholipids (21% in HP;
18% EC; and 15% PFC), with the major molecular species (in this
order): PS(18:0/22:6), and PS(18:0/18:1). Other relevant (and minor)
phospholipids at the mitochondrial level like PI and cardiolipin were
not analyzed. Currently, however, no additional information is avail-
able for a comprehensive atlas of the adult human brain lipidome.
From another approach, an interesting scenario can be drawn when
cross-regional diﬀerences in fatty acid proﬁles are considered. Fatty
acids are prime components of the structural diversity of lipids of any
cell type, neural cells included. Indeed, with diﬀerent permutations of
head group and fatty acids up to 10,000 theoretical lipid molecular
species can be generated [18]. Fatty acids also determine the functional
properties of lipids in brain which can be ascribed to their roles in the
structural and functional integrity of neuronal and glial cell mem-
branes, the generation of lipid signaling mediators, and the chemical
reactivity of the acyl chains [6]. In this context, a recent study ana-
lyzing the fatty acid composition of 12 diﬀerential regions of the adult
human central nervous system (from spinal cord to cerebral cortex)
[19] found shared traits such as an average chain length of 18 carbon
atoms, and a relative distribution between saturated (SFA) and un-
saturated (UFA) fatty acids of 40:60 (see Table 1).
When we focused on speciﬁc fatty acids, the ﬁndings showed that
the most diﬀerential fatty acids are 18:1n-9, 20:1n-9, 20:4n-6, 22:4n-6,
and 22:6n-3 [19] (see Table 1). Among these, the monounsaturated
fatty acid (MUFA) 18:1n-9 is the most abundant (with a cross-regional
range from 24% to 36%), whereas 22:6n-3 and 20:4n-6 are the most
abundant PUFAs in all regions, ranging (together) from 5% to 16%. The
ﬁnding that DHA (22:6n-3) is the main PUFA present in brain regions is
in line with previous ﬁndings pointing up the very high level of DHA in
the whole brain [4], but this is clearly in contrast to spinal cord and
medulla oblongata where the content is the lowest [19]. Interestingly, it
was observed that the greater the presence of MUFAs in a given region,
the lower the PUFA content.
For speciﬁc cross-regional diﬀerences in DHA (22:6n-3) content, it is
relevant to mention that these diﬀerences are due to variations in de-
saturase and peroxisomal beta-oxidation activity, enzymes involved in
the PUFA biosynthesis pathway. And more interestingly, this activity
can be speciﬁcally ascribed to neurons [19]. Consequently, the protein
expression linked to PUFA biosynthesis supports the cross-regional
diﬀerences in fatty acid proﬁles and suggests the possibility that neu-
rons can actively maintain their own compositional proﬁle.
2. Lipoxidative damage and human brain
2.1. Lipid oxidation and lipoxidation-derived molecular damage
Two traits of the membrane lipids determine their vulnerability to
lipoxidative damage: the physico-chemical properties of the membrane
Table 1
Fatty acid proﬁles of 12 diﬀerent regions from adult healthy human central nervous system.
Fatty Acid SC MO CB SN TH AM ST EC HC TC OC FC
14:0 1.9 1.8 1.1 1.3 1.3 1.2 1.0 0.8 1.3 1.0 1.2 1.3
16:0 18.2 18.2 25.5 20.2 20.5 24.3 21.6 21.8 22.1 23.4 23.7 20.0
16:1n−7 1.5 1.7 1.2 1.4 1.0 1.1 1.1 0.9 1.3 1.1 1.3 1.5
18:0 19.0 18.1 17.8 19.0 18.4 19.5 20.7 22.4 20.1 20.1 21.2 20.4
18:1n−9 36.2 36.7 23.9 32.1 29.5 24.9 25.7 28.0 27.0 24.3 24.8 24.6
18:2n−6 0.5 0.6 1.0 0.8 0.8 0.7 0.8 0.8 1.3 0.8 1.1 1.2
18:3n−3 0.2 0.3 0.2 0.2 0.3 0.1 0.4 0.1 0.1 0.2 0.1 0.2
18:4n−3 0.2 0.2 0.6 0.3 0.3 0.3 0.3 0.1 0.2 0.4 0.1 0.4
20:0 0.6 0.5 0.7 0.4 0.5 0.3 0.6 0.2 0.3 0.8 0.3 0.5
20:1n−9 6.3 4.6 1.2 2.5 2.2 0.9 1.6 1.2 1.3 1.1 1.3 1.7
20:2n−6 0.4 0.3 0.3 0.4 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.4
20:3n−6 1.4 1.4 1.5 1.3 1.4 1.2 1.1 1.0 1.2 1.4 1.4 1.1
20:4n−6 4.0 4.5 7.2 6.2 6.5 8.4 7.5 7.7 7.6 6.6 6.6 6.9
20:5n−3 0.3 0.2 0.4 0.4 0.5 0.3 0.4 0.1 0.3 0.4 0.3 0.4
22:0 0.6 0.6 0.5 0.6 0.6 0.3 0.5 0.2 0.5 0.5 0.3 0.5
22:4n−6 3.4 3.9 3.0 4.5 4.9 5.4 5.2 4.9 5.4 4.8 3.9 4.8
22:5n−6 0.3 0.4 1.1 0.5 0.8 0.9 0.9 0.8 1.1 0.9 0.7 1.0
22:5n−3 0.3 0.3 0.6 0.6 0.6 0.5 0.5 0.3 0.4 0.5 0.4 0.7
22:6n−3 1.7 2.2 10.0 5.0 6.8 7.5 7.1 7.1 6.6 9.3 9.4 10.4
24:0 1.4 2.1 0.7 0.8 1.0 0.7 0.9 0.4 0.7 0.8 0.4 0.9
24:5n−3 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.2
24:6n−3 0.4 0.4 0.3 0.3 0.4 0.2 0.4 0.04 0.1 0.2 0.2 0.1
ACL 18.1 18.2 18.3 18.2 18.4 18.3 18.4 18.3 18.3 18.4 18.3 18.5
SFA 41.8 41.5 46.6 42.5 42.5 46.5 45.6 45.9 45.2 46.8 47.3 43.7
UFA 58.1 58.4 53.4 57.4 57.4 53.4 54.3 54.0 54.7 53.1 52.6 56.2
MUFA 44.2 43.1 26.4 36.1 32.9 26.9 28.4 30.3 29.6 26.7 27.5 27.9
PUFA 13.9 15.3 26.9 21.3 24.5 26.4 25.9 23.7 25.1 26.4 25.0 28.2
PUFAn−3 3.6 4.0 12.5 7.4 9.4 9.2 9.7 8.0 8.1 11.4 10.8 12.6
PUFAn−6 10.3 11.2 14.3 13.9 15.0 17.2 16.1 15.7 16.9 15.0 14.2 15.6
DBI 101.6 107.2 152.7 130.2 143.5 146.5 145.3 137.4 140.9 149.6 144.2 160.0
PI 61.4 68.9 146.8 105.1 125.1 135.0 132.2 121.3 124.5 142.0 135.1 153.3
For fatty acids, values are means from 5 to 8 diﬀerent adult healthy subjects and are expressed as mol%.
Fatty acid indexes: ACL, average chain length; SFA, saturated fatty acids; UFA, unsaturated fatty acids; MUFA, monounsaturated fatty acids; PUFA n-6 or n-3,
polyunsaturated fatty acids n-3 or n-6; DBI, double bound index; PI, peroxidizability index. For calculations, see [19].
Abbreviations: SC, spinal Cord; MO, medulla oblongata; CB, cerebellum; SN, substantia nigra; TH, thalamus; AM, amygdala; ST, striatum; EC, entorhinal cortex; HC,
hippocampus; TC, temporal cortex; OC, occipital cortex; FC, frontal cortex.
Adapted with permission from Naudi et al. [19].
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bilayer and the chemical reactivity of the fatty acids that compose it
[20,21]. The ﬁrst property is based on the preferential solubility of
reactive species (e.g., free radicals) in the ﬂuid lipid bilayer instead of
in aqueous solution [22,23]. The second and more relevant property is
related to the fact that PUFA residues of lipids (and particularly Gpl) are
very sensitive to oxidation, and this sensitivity increases as a function of
the number of double bonds per fatty acid molecule [24–26]. So, PUFA
side chains (with two or more double bonds) are much more easily
damaged by reactive species than are MUFA (one double bond); while
SFA (no double bonds) are resistant to peroxidation.
Lipid peroxidation generates hydroperoxides and endoperoxides,
which undergo fragmentation to produce reactive intermediates with
diﬀerent carbons in length called reactive carbonyl species (RCS). The
most reactive RCS are α,β-unsaturated aldehydes [4-hydroxy-2-nonenal
(HNE) and acrolein], di-aldehydes [malondialdehyde (MDA) and
glyoxal], and keto-aldehydes [4-oxo-2-nonenal (ONE) and isoketals]
[27–30]. Special mention must be made of neuroketals (NKT) which are
keto-aldehydes formed by the non-enzymatic oxidation of the 22:6n-3
through the neuroprostane pathway [31]. 2-Hydroxyheptanal and 4-
hydroxyhexenal are other signiﬁcant aldehydic products of lipid per-
oxidation of PUFAs. Additional reactive compounds are the cyclo-
pentenone prostaglandins, levuglandins, or oxidized phospholipids,
among others [32]. Overall, these RCS are ubiquitously generated and
have two unique properties: i) a greater half-life compared with most
reactive oxygen species (ROS); and ii) a non-charged structure that
allows them to migrate easily through hydrophobic membranes and
hydrophilic cytosolic media, thereby extending the migration distance
far from the generation site [21].
RCS react with nucleophilic groups in macromolecules (lipoxidation
reactions) like proteins [32,33], DNA [34], and aminophospholipids
[35], resulting in their chemical, and non-enzymatic modiﬁcation. The
outcome is the generation of a diversity of adducts and intra- and inter-
molecular cross-links collectively named Advanced Lipoxidation
Endproducts (ALEs) [32,33,36] (see Fig. 2). Thus, by reacting with
nucleophilic sites in proteins (belonging basically to Cys, Lys, Arg, and
His residues), RCSs generate ALE adducts such as MDA-Lys, HNE-Lys,
NKT-lys, FDP-Lys, carboxymethyl-lysine (CML), and S-carboxymethyl-
cysteine, as well as the cross-links glyoxal-lys dimer (GOLD), and lys-
MDA-lys, among others. The accumulation of MDA adducts on proteins
is also involved in the formation of lipofuscin, a non-degradable in-
tralysosomal ﬂuorescent pigment formed through lipoxidation reac-
tions already described in human neurons by Hannover in 1842
[37,38]. Most of these compounds have been detected, characterized,
and located (by mass spectrometry, redox proteomics, and im-
munohistochemistry) in the human brain. RCSs can also react with the
exocyclic amino groups of deoxyguanosine, deoxyadenosine, and
deoxycytosine to form alkylated products. Guanine is the most prone
and commonly modiﬁed DNA base because of its high nucleophilicity,
and MDA-deoxyguanosine (M1dG) is the most common adduct. Finally,
the amino group of aminophospholipids can also react with RCS,
leading to the formation of adducts such as MDA-PtdEtn, and carbox-
ymethyl-PtdEtn. The molecular consequences derived from ALE for-
mation include protein alterations in physico-chemical properties (e.g.,
conformation, charge, hydrophobicity, and solubility), formation of
intra- and inter-molecular protein crosslinks and aggregates, loss of
enzymatic activity, DNA damage and mutagenesis, and alterations in
physico-chemical and biological properties of the lipid bilayer [21,36].
Beside the cytotoxic eﬀects, RCSs can also work as regulatory sig-
nals inducing adaptive responses speciﬁcally designed to decrease li-
poxidative damage and improve antioxidant defenses [21,36,39]. Two
of these mechanisms involved in the modulation of oxidative stress by
RCS are: i) the modiﬁcation and activation of uncoupling proteins
(UCPs) by the RCS hydroxynonenal and the subsequent decrease in
mitochondrial ROS production [40,41], and ii) the activation of the
antioxidant response signaling pathway (Nrf2 pathway) that includes,
among others, the expression of enzymes such as glutathione-S-
Fig. 2. General structures of principal reactive carbonyl species (RCS) detected in human brain. RCSs can react with nucleophilic groups in macromolecules (proteins,
DNA and lipid species–aminophospholipids) resulting in their chemical, non-enzymatic and irreversible modiﬁcation leading to the formation of a variety of adducts
and crosslinks collectively called Advanced Lipoxidation End-products (ALEs).
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transferase (GST) speciﬁcally designed to detoxify reactive carbonyl
compounds [42,43], and GPx4 (phospholipid hydroperoxide glu-
tathione peroxidase) designed to restore reduced states of membrane
fatty acids from phospholipids to ensure membrane lipid homeostasis
[44–47].
2.2. Cross-regional diﬀerences in vulnerability to lipoxidative damage
The high concentration of PUFAs in neuronal and glial cell mem-
brane Gpl not only makes them prime targets for lipoperoxidative da-
mage but also enables them to participate in long free radical chain
reactions. Thus, from a given membrane fatty acid proﬁle it is possible
to calculate its peroxidizability index (PI) by combining this composi-
tion with the relative susceptibility of individual fatty acids to perox-
idation. So, PI is a measure of the relative susceptibility of a given
membrane fatty acid composition to peroxidative damage. The higher
the value of PI, the greater the susceptibility of the membrane bilayer to
lipid peroxidation [20,21].
Available evidence comparing 12 brain regions (spinal cord, me-
dulla oblongata, cerebellum, substantia nigra, thalamus, amygdala,
striatum, entorhinal cortex, hippocampus, temporal cortex, occipital
cortex, and frontal cortex) reveals the presence of cross-regional dif-
ferences in the PI in the human central nervous system and, conse-
quently, establishes a region-dependent vulnerability [19] (see
Table 1). In order to learn whether these diﬀerences followed a speciﬁc
pattern, the relationship between the PI and their distribution ac-
cording to the main subdivisions of the embryonic vertebrate brain
following the caudal-cranial axis (from spinal cord to cerebral cortex)
was evaluated [19]. The results demonstrated that the higher (more
cranial) the brain region, the greater the PI. However, a greater PI is not
necessarily associated with a higher degree of molecular damage. In
fact, the case is quite the reverse. Thus, the higher the PI of the analyzed
regions, the lower the lipoxidation-derived protein damage. This dis-
sociation is due to the lower mitochondrial stress in the superior brain
regions, and better neuronal adaptive response mediated by the anti-
oxidant response-signaling pathway Nrf2 [19].
The cross-regional vulnerability diﬀerences have been also evi-
denced using a redox proteomics approach. Thus, a recent study ana-
lyzed, by western blot, levels of protein adduction by lipid peroxidation
(LP) end-products neuroketal (NKT) and malondialdehyde (MDA), as
markers of protein lipoxidative damage, in twelve brain regions in
normal middle-aged individuals [48]. The ﬁndings demonstrated that
the degree of molecular damage is region-dependent. Reinforcing this
observation, another work using a redox proteomic proﬁling of neu-
roketal-adducted proteins in three human brain regions also veriﬁed a
diﬀerential regional vulnerability [49].
Together, available evidence conﬁrm the existence of a region-de-
pendent vulnerability and the presence of cross-regional diﬀerences to
lipoxidative damage in healthy adult human brain.
3. Lipids and lipoxidative damage during human brain aging
3.1. Lipids and brain aging
The physiological aging process induces changes at all levels of the
biological organization which are oﬀset by allostatic adaptive response
mechanisms geared to preserving the composition and function within
homeostatic limits. The cell membrane is not an exception, and, con-
sequently, the longer the optimal membrane lipid composition is
maintained, the better the cell survival and function [50]. However,
deterioration in structure and function of the adult human brain during
aging is not uniform throughout the brain. Consequently, human brain
aging must be considered as a heterogeneous process probably subject
to region-speciﬁc (and even cell-speciﬁc) vulnerability. Yet, regional
vulnerability is often ignored in the study of brain aging. Regional
vulnerability refers to the particular sensitivity of a given region to
damage by distinct noxious stimuli and to its speciﬁc capacity to re-
spond with the appropriate defenses. In this framework, it is plausible
to hypothesize that cross-regional diﬀerences in human brain lipid
composition, in addition to diﬀerences in oxidative stress conditions,
could be responsible for this vulnerability which, in turn, leads to dif-
ferent rates of aging.
Two early studies, from the 1950s and 1960s [51,52], both per-
formed in whole brain samples, oﬀered the ﬁrst evidence that the
membrane lipid composition of the human brain changes with aging.
They found that the amount of total lipids decreased after the second
decade of life. Subsequent studies conﬁrmed the occurrence of age-re-
lated lipid alterations in diﬀerent areas of human brain. Overall, the
described changes are aligned to the progressive and deleterious char-
acter of the aging process, and demonstrate that concentrations of most
lipids in the human brain decrease after the age of 50. Nevertheless, the
brain levels of diﬀerent Gpls like PI, PE, and PC decrease very slowly
with age, with less than 10% loss in the period between 40 and 100
years of age [53]. In another study, 10–20% loss of Gpl in diﬀerent
brain regions (gray matter, white matter, nucleus caudatus, hippo-
campus, pons, cerebellum, and medulla oblongata) was observed only
in 90-year-olds compared to 35-year-olds, while phospholipid compo-
sition in various brain regions remained unchanged during aging [54].
In a similar way, another work found that the Gpl decrease starts slowly
after age 20, and after age 80 becomes more pronounced, with no
signiﬁcant diﬀerence in lipid proﬁle between male and female brains
[55,56]. It has been also described how PE(P-) brain levels decrease
18% (till the age of 70) and 29% (till the age of 100), and SM brain
levels decrease 12% and 20% in the same time period, respectively
[57]. The eﬀect of region-speciﬁc aging on brain cholesterol content has
been also described. Thus, the studies of Svennerholm et al. [56] and
Söderberg et al. [54] reported a reduction in cholesterol levels starting
at 20 years of age in human frontal and temporal cortices, as well as
hippocampus, nucleus caudatus, medulla oblongata, and cerebellum.
More recent studies focused on the mitochondrial and microsomal
lipidome of frontal cortex, hippocampus, and entorhinal cortex of
subjects from 20 to 100 years old [15–17], showing that minor lipid
molecular species of Gpl from PC, PE, and PS classes and containing
adrenic acid (22:4n-6) and AA speciﬁcally decreased along adult life in
the three regions of the cerebral cortex, whereas particular PC, PE, and
PS containing DHA increased or remained the same during the same
period. Similarly, minor changes or none at all were observed in the
distribution of lipid classes and fatty acid composition of lipid rafts
from normal human frontal cortex throughout the human lifespan
(24–85 years) [58].
An additional research line comes from studies focused on the
analysis of the fatty acid compositional proﬁle in diﬀerent regions of
the human cerebral cortex such as orbitofrontal cortex (OFC, Brodmann
area 10) [59], prefrontal cortex [15], frontal cortex (area 8) [60], en-
torhinal cortex [17], and hippocampus [16], in healthy subjects ranging
from 20 to 80 years old. No data are available from other regions of the
human central nervous system. The ﬁndings of these studies point to
some basic ideas: i) a general sustained and preserved fatty acid proﬁle
throughout the adult lifespan in most studied regions; ii) maintenance
or minor changes with age in the saturated and monounsaturated fatty
acid content; iii) decrease in the PUFA content from series n-6 with age,
particularly aﬀecting 20:4n-6 and 22:4n-6; and iv) maintenance or
minor increase in 22:6n-3 content during aging with eventual reduction
at a very advanced age.
Sustained SFA, MUFA, and DHA content with age could be inter-
preted as an adaptive response to aging to preserve neurons and cere-
bral function by helping to maintain the geometric properties of lipids
and, consequently, functional properties such as exocytosis and mem-
brane domain formation [5]. The meaning of changes (though minor)
in the average chain length and double bond index at advanced ages,
which can also inﬂuence the geometric properties of lipids and their
functional properties, remains to be explored. In contrast to these
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observations, decreases in PUFAn-6, and particularly the 20:4n-6 and
22:4n-6 fatty acid content, could have biological eﬀects in that they are
substrates for lipid mediators. Thus, one explanation for this ﬁnding lies
in the reported decline in the PUFA biosynthesis pathway [60]; but
there is also increased consumption by enzymes involved in anti-in-
ﬂammatory pathways which synthetize a diversity of compounds with
neuroprotective properties to ensure cell survival and functioning
during normal aging [60]. For this reason it is proposed that during
normal human brain aging, the lipid proﬁle is particularly resistant to
changes with age because they are under strict control to ensure neu-
ronal survival and function.
Overall, the available evidence suggests that major adult human
brain lipids undergo slight but progressive and signiﬁcant changes in
their concentrations and distribution during the aging process.
However, the individual contribution of these lipid patterns to the aging
process is as yet unknown. Therefore, a goal of future research is to
deﬁne which types of lipids change with age in the diﬀerent human
brain areas and how they relate both to the function of the area and to
the dysfunction leading to neuropathology. Indeed, it is not yet known
whether the changes in the conﬁrmed lipids represent neutral changes
with age, changes causing physiological aspects of aging, or rather are
beneﬁcial responses to damaging agents. In any case, the described
ﬁndings suggest that lipid species and their metabolism are closely
linked to human brain aging.
3.2. Cross-regional diﬀerences in lipoxidative damage during human brain
aging
Although the membrane lipid composition is largely maintained to
guarantee cell survival and function, there is a continuous physiological
lipoperoxidative attack on the membrane, and this membrane becomes
a source of carbonyl compounds with the ability to damage other cel-
lular components. Consequently, it is suggested that progressive li-
poxidation-derived molecular damage is a conserved, central me-
chanism of age-related functional decline in human brain.
Thus, recently, the ﬁrst study analyzing selective and speciﬁc pro-
tein damage markers by mass spectrometry in frontal cortex from
healthy human covering a range of age between 43 and 86 years old
was published [61]. The results demonstrated that there is an increase
in the steady-state level of protein oxidative and lipoxidative damage in
human frontal cortex over the adult lifespan, with a breakpoint at 60
years of age (the detected and quantiﬁed markers for protein oxidation
were glutamic semialdehyde and aminoadipic semialdehyde; and car-
boxymethyl-lysine (CML) and carboxyethyl-lysine (CEL), for protein
lipoxidation). This increase seems to be selective because temporal
trajectories for the steady-state level of markers derived from the non-
enzymatic modiﬁcation of cysteine residues (carboxymethyl-cysteine,
CMC; and succinyl-cysteine, SC) remained unchanged with age. This
dissociation in the behavior of the diﬀerent protein damage markers
analyzed may be ascribed to the cellular homeostatic mechanisms be-
hind their formation. Thus, the increase in the oxidation markers may
reﬂect an increase in the net ﬂux of free radical generation, but also a
decrease in the activity of protein turnover mechanisms; and for protein
lipoxidation, the increased levels can express an increased oxidative
stress status (again free radical generation and protein turnover), but
also an increased level in the content of PUFAs which act as substrate
for the formation of RCS and these markers. In contrast, the unchanged
content in markers derived from cysteine modiﬁcation may be an in-
dication of better preservation of cysteine residues and their function-
ality by speciﬁc repair mechanisms over the adult life-
span—mechanisms which are absent for other kind of markers. The
presence of other kind of nonenzymatic modiﬁcations aﬀecting cysteine
residues cannot be discarded.
In another recent work [49] the regional diﬀerences in the protein
damage markers derived from the RCS neuroketals (NKT) and mal-
ondialdehyde (MDA) in twelve brain regions (frontal cortex area 8,
parietal cortex area 7, inferior temporal cortex area 20, occipital cortex
17–18, cingulate gyrus area 24, entorhinal cortex, hippocampus, head
of the caudate, anterior putamen, thalamus, substantia nigra, and upper
vermis) in two groups of individuals, middle-aged and old-aged, were
analyzed. The middle-aged group presented no neuropathological le-
sions and the old-aged group presented neuroﬁbrillary tangles (NFT)
pathology at stage I-II considered consistent with normal brain aging
[62,63]. Steady state levels of these markers were also analyzed as a
function of age as continuous variables. The levels of NKT-modiﬁed
proteins showed discrete regional variations in old-aged human brain.
NKT-protein adducts were increased in frontal cortex, visual cortex, and
substantia nigra, and reduced in thalamus when comparing the two
groups. However, only NKT-protein adduct levels in the thalamus re-
mained signiﬁcantly decreased considering age as a continuous vari-
able. In addition, reduced NKT adducts with age were identiﬁed in the
putamen.
In contrast to NKT, MDA-lys showed wide regional presentation in
aged human brain. Furthermore, this non-enzymatic modiﬁcation af-
fected more regions in old age when compared with NKT. Five brain
regions display increased MDA protein adduction in old-aged in-
dividuals, including frontal cortex, parietal cortex, hippocampus, tha-
lamus, and putamen. Curiously, decreased levels of MDA adduction
with age occur in temporal cortex and entorhinal cortex when com-
paring middle-aged with old-aged individuals. However, only increased
MDA protein adduction in frontal cortex, parietal cortex, and thalamus,
and reduced MDA adduction in entorhinal cortex, remain signiﬁcant
when considering age as a continuous variable. Signiﬁcantly reduced
MDA adducts in the temporal cortex and increased adducts in the pu-
tamen were additionally recognized. Interestingly, in addition to MDA-
lys, lipofuscin shows a nearly linear accumulation with age in the
nervous system [64,65]. Whether regional lipofuscin deposition paral-
lels regional accumulation of MDA adducts invites additional study.
So, the present ﬁndings show unexpectedly few variations restricted
to certain brain regions and mainly involving the production of MDA
adducts. It would be interesting to integrate trajectories of diﬀerent
variables like free radical production, changes in fatty acid proﬁle, and
lipoxidative damage to explain the diﬀerential impact of aging ac-
cording to the brain region.
4. Selectivity of lipoxidation-derived molecular damage in human
brain
4.1. Selective protein lipoxidation in human brain and during brain aging
Although the steady state levels of ALEs in proteins increase in
human brain in a region-speciﬁc way during aging, such evidence does
not elucidate the speciﬁc mechanisms that cause losses in particular
cellular/tissue functions. Is there a selective pattern of lipoxidative
protein damage? If true, what are the protein targets? Why this pool of
proteins (if any) is modiﬁed? What is the putative mechanism by which
selective protein damage plays a causal role in aging? Few studies have
addressed these questions.
The human transcriptomics study demonstrates the existence of
20,344 putative protein-coding genes, with about 74% of these genes
expressed in the brain compared to other human tissues [66]. More
speciﬁcally, in total 10,465 protein entries (corresponding to 7797
protein-coding genes) have been detected and identiﬁed in healthy
human brain by mass spectrometry-based proteomics [67]. Assuming
this number of brain proteins, available evidence demonstrates that
only 0.7% of the healthy adult brain proteome is lipoxidatively mod-
iﬁed (71 proteins from 10,465) (see Table 2). Importantly, the degree of
lipoxidative damage increases with age, and in all the identiﬁed pro-
teins increased lipoxidation is not due to a higher content of the cor-
responding protein but rather to increased ﬂux of protein damage. This
small but signiﬁcant pool of lipoxidized protein probably will increase
with time because i) currently available studies are exclusively
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restricted to diﬀerent areas of the human cerebral cortex (e.g. parietal
cortex, frontal cortex, temporal cortex, entorhinal cortex, cingulate
gyrus, and hippocampus), and ii) the ALEs detected are limited to those
derived from HNE, lipofuscin, MDA, and NKTs. Consequently, further
studies extending analyzed brain regions and the lipoxidation markers
detected are needed to obtain a more detailed view.
The potential selectivity of lipoxidation and its derived molecular
damage is supported by several works (some articles/reviews addres-
sing the topic of the selectivity of lipoxidation in diﬀerent experimental
models are [68–71]. In proteomic studies, frequently only a subset of
proteins is found to get modiﬁed in a complex system, and only one or a
few residues become adducted in a given protein, generally, residues
with particularly low pKa or high reactivity. Also the structure of the
modifying species inﬂuences the selectivity of the modiﬁcation.
The structural characterization of the modiﬁed proteins in the
healthy adult human brain with PredictProtein software analysis
(https://www.predictprotein.org/) reveals some shared speciﬁc traits
which may explain this speciﬁcity rendering proteins more susceptible
to oxidative damage [48]. Thus, i) the predominant structures of li-
poxidized proteins are alpha helix and loops, ii) most proteins (ex-
cepting cytoskeletal proteins) are globular and form soluble coiled-
shaped molecules with hydrophobic groups at the core and exposed
hydrophilic groups to the medium, and iii) among the most recurrent
amino acids encountered in the exposed regions is lysine, in addition to
glutamic acid and aspartic acid, a frequent target of non-enzymatic
modiﬁcation on proteins.
Another factor that may be important in the selectivity of modiﬁed
proteins is the spatial location. Localization of proteins may make them
more vulnerable as a result of their environmental conditions.
Positioning refers to a particular cell type or to a subcellular compart-
ment. From data in Table 2, an example of cell type-related vulner-
ability is GFAP localized in astrocytes which are brain producers of
DHA and its lipid peroxidation derivatives. Regarding subcellular lo-
calization, several lipoxidized proteins are located in the mitochondria,
the principal source of damaging free radicals; other proteins are lo-
cated in membranes belonging to diﬀerent subcellular compartments or
even cell membranes, which show a high content in PUFAs. In contrast,
other damaged proteins are those of the cytoskeleton, or they are lo-
cated in the growth cones, involved in neurotransmission, or present in
synaptic vesicles. It is worth stressing that axons and synaptic terminals
have high bioenergetic demands achieved by continuous mitochondrial
activity and recruitment, and rapid energy transduction. In addition,
axons are radial structures with a small diameter in comparison with
the cell body which heightens the probability of stochastic interactions
between free radicals and membrane lipids, thus propitiating lipid
peroxidation and further non-enzymatic modiﬁcation of proteins.
Overall, these observations show that i) the cerebral cortex in
healthy adults contains lipoxidized proteins, the levels of which vary
among regions, ii) the ALE-modiﬁed proteins increase in aged subjects,
and iii) the selectivity of molecular damage is associated with speciﬁc
structural traits and spatial location.
4.2. Functional clustering of lipoxidatively-damaged proteins
The identiﬁcation of speciﬁc lipoxidation-modiﬁed proteins in the
brain of adult and aged subjects provides an overview of the selective
cellular functions that are aﬀected during the aging process. The pro-
teins listed in Table 2 show us the biological processes aﬀected by RCS-
related protein damage. If we consider these molecular pathways, we
verify that energy metabolism (with 31% of modiﬁed proteins, n= 22),
neurotransmission (including neuronal communication, synaptic plas-
ticity, and other processes) (with 25% of modiﬁed proteins, n= 18),
and cytoskeleton (17% of modiﬁed proteins, n= 12) are the main af-
fected cellular functions. Other signiﬁcant molecular pathways in-
volved but with a lesser number of modiﬁed proteins are proteostasis
(9.8%, n=7 modiﬁed proteins), antioxidants (5.6%, n=4), O2/CO2/
heme metabolism (4.2%, N03), transport (4.2%, n=3), and signal
transduction (2.8%, n= 2).
There is an extensive evidence that energy metabolism is particu-
larly aﬀected during aging [8,72–74]. The reported observations give
some clues about the molecular substrates of energy failure with aging
after the identiﬁcation of key proteins as targets of lipoxidative damage
including proteins of glycolysis ENO1, ENO2, ALDO A, GAPDH, LDHB,
PGK1, PGAM1, PKM, and TPI1; proteins of the tricarboxylic acid (TCA)
cycle ACO2, GLUD1, and MDH2; protein subunits of the mitochondrial
electron transport chain complexes COX5A, DLD, NDUFS3, and
UQCRC1; and diﬀerent protein subunits of mitochondrial ATP synthase
or complex V responsible for oxidative phosphorylation. All of these
proteins are components of coupled processes which are necessary to
fulﬁll the ATP requirements of cells. Neuronal activity is highly de-
pendent on these processes since, in normal conditions, glucose is the
exclusive energy substrate for the brain [75]. In addition, CKB and
CKMT1A are in charge of rapid ATP production from phosphocreatine
reservoirs in response to acute increased energy demands in neurons,
but both proteins are also key players in the ‘phosphocreatine circuit’
for cellular energy homeostasis [76]. Thus CKB and CKMT1A provide
neurons with a reservoir and also an alternative source of ATP to gly-
colysis, TCA cycle, and respiration.
The second major biological process that is aﬀected during aging
based on the number of lipoxidized proteins is neurotransmission
[38,48,77–81]. The 18 aﬀected proteins are: GOT1, BASP1, CAMK2A,
CLTC, CNP, DPYSL2, GLUL, CD47, LSAMP, PEBP1, YWHAG, YWHAE,
YWHAZ, SYN1, SNAP25, STX1B, STXBP1, and VAMP2. These proteins
are involved in several functions such as neurotransmitter metabolism,
axon growth and guidance, growth cone collapse and cell migration,
neuron diﬀerentiation, synaptic transmission and plasticity, synaptic
vesicle traﬃcking, signaling pathways, and regulation transcriptional
activity, among others. These modiﬁcations together with those linked
to the high energy demands make synapses especially vulnerable to
oxidative stress damage. Interestingly, these biological processes po-
tentially aﬀected by the modiﬁed proteins are aligned with the concept
that most of the functional decline associated with normal brain aging
is caused by relatively subtle changes such as changes in the molecular
proﬁle of synapses, altered spine morphologies, reductions in spine
densities, or loss of dendrites [7,82].
Cytoskeletal proteins are also lipoxidized being the third major
biological process with a great number of modiﬁed proteins (n=12).
The aﬀected proteins are: beta-Actin, dynamin 1, glial ﬁbrillary acidic
protein, neuroﬁlament light polypeptide, neuroﬁlament medium poly-
peptide, spectrin alpha chain brain, spectrin beta chain brain 1, thy-1
membrane glycoprotein, tubulin alpha 1B chain, tubulin beta chain,
tubulin polymerization-promoting protein (TPPP), and vimentin. Thus,
proteins belonging to the main components of cytoskeleton seem to be
aﬀected: microﬁlaments, intermediate ﬁlaments, and microtubules.
These ﬁndings are in line with previous observations showing that
neuroﬁlaments are major targets of HNE adduction in mice nervous
system [83,84]. Consequently, general neuronal and glial processes
linked to cytoskeleton such as the cytoskeleton organization itself, cy-
toskeleton-dependent intracellular transport, and maintenance of the
integrity of the microtubule network and microtubule-based processes
can become dysfunctional as a consequence of the non-enzymatic
modiﬁcation of their protein components. But additional functions
more speciﬁcally linked to neural cells which require cytoskeleton in-
tegrity can also be aﬀected secondarily to protein lipoxidation [7,82].
Among these functions are vesicle traﬃcking, synaptic plasticity, axon
guidance, development of the central nervous system, maintenance of
the neuronal caliber, and synaptogenesis.
Seven damaged proteins are involved in proteostasis. These proteins
are: alpha-crystallin B chain (heat shock protein B5) (CRYAB), elon-
gation factor Tu (TUFM), eukaryotic translation initiation factor 2A
(EIF2A), heat shock protein 60KDa (HSPD1), heat shock protein 70KDa
protein 1A (HSPA1A), protein/nucleic acid deglycase DJ-1 (PARK7),
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and ubiquitin carboxyl-terminal hydrolase L1 (UCHL1). Whereas TUFM
and EIF2A are involved in protein biosynthesis and HSPD1 participates
in mitochondrial protein import and macromolecular assembly, folding
of proteins, and apoptotic process, the rest of the proteins (UCHL1,
CRYAB, HSPA1A, and PARK7) play a relevant role in oxidative stress
homeostasis. Thus, UCHL1 participates in processing of ubiquitin pre-
cursors and ubiquitinated proteins for proteasomal degradation [85],
and CRYAB shows chaperone-like activity and prevents aggregation of
proteins under stress conditions [86]. HSPA1A is a molecular cha-
perone involved in the protection of the proteome from stress, playing a
pivotal role in the protein quality control system, ensuring the correct
folding of proteins and the re-folding of misfolded proteins, and con-
trolling the targeting of proteins for subsequent degradation [87–89].
PARK7 is a protein and nucleotide deglycase that catalyzes the de-
gradation of adducts formed between amino groups of proteins or nu-
cleotides and RCS. Thus, it functions as a protein repair system [90–93].
It deglycates cysteine, arginine, and lysine residues in proteins, and
thus reactivates these proteins by reversing non-enzymatic modiﬁcation
by RCS. Analogously, it also functions as a nucleotide deglycase able to
repair modiﬁed guanine in the free nucleotide pool (GTP, GDP, GMP,
dGTP) and in DNA and RNA. Furthermore, it plays an important role in
cell protection against oxidative stress and cell death, acting as an
oxidative stress sensor and redox-sensitive chaperone and protease. And
ﬁnally, it is involved in neuroprotective mechanisms linked to mi-
tochondrial uncoupling proteins, L-type channels, and inﬂammatory
responses. So the modiﬁed chaperones are deeply involved in main-
taining neuronal oxidative stress homeostasis. Assuming that none-
nzymatic modiﬁcations are mostly linked to the loss of function, it may
be proposed that the inactivation of the modiﬁed chaperones
[85,92,94,95] are involved in brain aging by promoting cellular oxi-
dative stress.
Reinforcing the dysfunction in oxidative stress homeostasis derived
from the modiﬁed chaperones, lipoxidation-derived damage also aﬀects
some antioxidant enzymes such as carbonyl reductase (NADPH)1
(CBR1), hemeoxygenase 1 (HMOX1), manganese superoxide dismutase
(SOD2), and peroxiredoxin 6 (PRDX6). CBR1 participates in the re-
duction of carbonyl compounds; HMOX1 has cytoprotective eﬀects
since an excess of free heme sensitizes cells to undergo apoptosis; SOD2
destroys superoxide radicals generated by mitochondrial complex I and
III (the main cell generators of free radicals), and PEDX6 has anti-
oxidant properties.
Three proteins related to heme metabolism and O2 and CO2 reg-
ulation, biliverdin reductase B (BLVRB), carbonic anhydrase (CA), and
hemoglobin 1 A (HB1A), are also lipoxidatively damaged. CA partici-
pates in the conversion of CO2 into bicarbonate and participates in the
transport of CO2 out of the tissues. BLVDR regulates the ﬁnal step in
heme metabolism, but it also regulates glucose metabolism and has
neuroprotective eﬀects [96]. HBA1 is a component of hemoglobin, the
role of which in the nervous system is still poorly understood. He-
moglobin has been found in neurons where it probably plays a role in
O2 transport or in the regulation of cytosolic neuronal O2 [97]. Lipox-
idative damage to these three proteins tags cell O2 and CO2 regulation
as a target of putative cellular respiratory dysfunction in the elderly.
Finally, molecular interactions of lipoxidized proteins in the human
cerebral cortex were explored to identify systems that may be indirectly
impaired as a result of primary protein lipoxidation and presumed loss
of function. Ubiquitin C has been identiﬁed as the central node of the
network of interactions [48]. Ubiquitin conjugation to proteins plays a
cardinal role in the ubiquitin/proteasome system and protein turnover
which has been identiﬁed as being aﬀected by aging [98,99]. Since
ubiquitin conjugation to target proteins occurs through the ε-amino
group of lysine, RCS adduction of this group can restrain protein-ubi-
quitin interactions and then hamper the degradation of altered proteins.
In addition, 50% of the ubiquitin binding sites are not involved in
protein degradation by the ubiquitin/proteasome system [100], thus
suggesting that ubiquitin serves in other molecular pathways. If true,
several pathways can be deregulated as a result of altered ubiquitin
conjugation with lipoxidized proteins [101].
5. ATP-synthase is a key lipoxidative target in human brain aging
5.1. Human ATP-synthase structure and function
Mitochondrial dysfunction and energy metabolism deﬁciencies have
been recognized as molecular events in human brain aging and have
been correlated with impairments of cognitive abilities. ATP synthase is
a macromolecular structure located in the inner mitochondrial mem-
brane and is the last complex (complex V) of the electron transport
chain to play a key role in energy metabolism. Complex V has a central
role in cellular energy (as ATP) supply.
Human mitochondrial ATP synthase is a complex of 583 kDa. It is
composed of 15 diﬀerent protein subunits and organized into two do-
mains: a membrane-extrinsic and matrix-oriented F1 (371 kDa) cata-
lytic domain, and a membrane-embedded F0 (212 kDa) domain, the
two connected by a peripheral and central stalk [102–106]. More
speciﬁcally, the F0 domain is a trans-membrane channel that translo-
cates protons and F1, a synthase domain that binds to ADP and in-
organic phosphate and synthesizes ATP on its surface. The coupling
between F0 and F1 and coordination of conformational changes of their
subunits is critical for eﬃcient ATP generation.
The F1 domain is composed of 5 subunits with a stoichiometry of
α3β3γδε; the component (αβ)3 is the catalytic head and fundamental
structure into which the γδε central stalk rotor penetrates. The F0 do-
main consists of 10 subunits: a, b, c, d, e, f, g, OSCP (oligomycin sen-
sitivity conferring protein), F6, and A6L. These subunits shape a ring
that shuttles protons across the membrane, forms the peripheral stalk
connecting the catalytic head to the membrane stator, and participates
in the formation of ATP synthase dimers [107] that self-assemble in
longer ribbons important for cristae formation [108,109].
F0F1 ATP synthase activity is regulated by several factors such as
membrane electrochemical potential, allostery, including ATPase in-
hibitory peptides, and protein synthesis [102], as well as membrane
lipid environment [110], and post-translational modiﬁcations [111].
Interestingly, some of the functional properties of ATP synthase and
regulatory mechanisms are linked to the integrity of speciﬁc residues
such as lysine, arginine, and cysteine [102,110,111]. Thus, for instance,
speciﬁc post-translational and reversible modiﬁcations like acetylation
and methylation play important roles in ATP synthase regulation by
modifying ε-amino groups of lysine, with the resulting conformational
changes of the active sites and decreased enzymatic activity [111]. In a
similar way, the integrity of structural lysine residues is a key point to
promote the interaction with membrane lipids, particularly cardiolipin,
in order to ensure correct ATP synthase activity [110].
5.2. ATP-synthase as target of lipoxidative damage in human brain aging
Available evidence demonstrates that ATP synthase is a system-
atically damaged key protein. The lipoxidation-derived protein adducts
described are formed from hydroxynonenal, malondialdehyde, neuro-
ketals, or lipofuscin (see Table 2). Lipoxidation damage aﬀects pre-
ferentially, but not exclusively, to subunits α and β (see Table 2); al-
though the speciﬁc residues targeted are still unknown. The
immunohistochemical studies suggest that the only cell type damaged
are neurons [80]; modiﬁed ATP synthase has been detected in diﬀerent
regions of the human cerebral cortex, and this lipoxidation-derived
protein damage increases in the elderly [48,80,112].
This preferential and selective non-enzymatic modiﬁcation of ATP
synthase is related to several factors such as structural traits, location,
and functional characteristics that can inﬂuence this speciﬁcity (see
Fig. 3). Concerning structural traits, it has been demonstrated that the
presence of alpha helices and loops, globular shapes that additionally
form soluble coiled-shaped molecules with hydrophobic groups to the
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center and exposed hydrophilic groups, and the presence and exposure
of amino acids like lysine which are particularly vulnerable, render ATP
synthase susceptible to lipoxidative damage [48]. As to location, ATP
synthase is a mitochondrial complex located inside the inner membrane
and oriented toward the mitochondrial matrix. Thus, ATP synthase is
exposed to a potentially dangerous environment because of proximity
to the main generators of free radicals (mitochondrial complex I and III)
at the cellular level, and its insertion in a lipid bilayer highly enriched
in PUFAs.
The non-enzymatic modiﬁcation of the speciﬁc subunits α and β
probably changes ATP-synthase conformation, leading to the inactiva-
tion of the complex and defects in ATP synthesis. It has been demon-
strated that ATP synthase activity is decreased in the cerebral cortex of
aged individuals [80]. Importantly, ATP synthase lipoxidation and its
loss of activity are not accompanied by reduced total expression levels
of this protein [80]. In fact, it is documented that ATP synthase content
does not change with age [61]. Therefore, the non-enzymatic and ir-
reversible modiﬁcation by carbonyl compounds derived from lipid
peroxidation of ATP synthase likely explains their reduced activity and
reduced ATP levels during the human brain aging process. Further-
more, this loss of ATP synthase activity can aﬀect the electron transport
chain, inducing a mitochondrial dysfunction leading to increased re-
active oxygen species production, and consequently impairment, in
cellular oxidative stress conditions, with the subsequent neuronal da-
mage.
6. Conclusions
Overall, the available evidence provides robust information about
increased steady state levels of protein damaged by lipoxidation reac-
tions with aging in a region-speciﬁc way which may compromise vital
cell functions such as energy metabolism, neurotransmission, cytoske-
leton, proteostasis, antioxidants, and O2/ CO2/heme homeostasis. Post-
translationally modiﬁed proteins resulting from lipoxidative damage
may be considered putative collaborative factors contributing to neu-
ronal aging. Protein vulnerability to non-enzymatic modiﬁcations is
related to the particular structural traits and spatial location at the
subcellular level. Mitochondrial ATP synthase is a key lipoxidative
target in human brain aging. Importantly, since lipoxidative damage to
proteins is already identiﬁed in middle-aged normal individuals and
increases physiologically in the elderly, it seems reasonable to act upon
the appropriate free radical-producing targets and lipid metabolism at
the appropriate middle-age window.
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